Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Observational × Lung Neoplasms × anlotinib × Clear all

Status

Sponsor Class

Study Type

Interventional 8 Observational 1

Sponsor

Cancer Type

Conditions

Thyroid Neoplasms 2 Esophageal Neoplasms 2 Lung Neoplasms 1 Liver Neoplasms 1 Colonic Neoplasms 1 Carcinoma, Non-Small-Cell Lung 1 Breast Neoplasms 1

Interventions

Surveys and Questionnaires 21 Blood Specimen Collection 21 Gene Expression Profiling 12 Radiotherapy 11 Magnetic Resonance Spectroscopy 9 Immunohistochemistry 9 Drug Therapy 9 Surgical Procedures, Operative 8 Specimen Handling 8 Polymerase Chain Reaction 7 Bronchoscopy 7 Amplified Fragment Length Polymorphism Analysis 7 pembrolizumab 6 Psychiatric Rehabilitation 6 Observation 6 Interviews as Topic 6 Carboplatin 6 Tomography, X-Ray Computed 5 Thoracic Surgery, Video-Assisted 5 Reverse Transcriptase Polymerase Chain Reaction 5 Liquid Biopsy 5 durvalumab 4 Therapeutics 4 Paclitaxel 4 Microarray Analysis 4 Ipilimumab 4 Immunotherapy 4 Biopsy 4 Bevacizumab 4 osimertinib 3

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT05319886 2022-05-20

AP

The First Affiliated Hospital of Xinxiang Medical College

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡